Articles with "ctdna" as a keyword



Photo by cesarfrv93 from unsplash

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies

Sign Up to like & get
recommendations!
Published in 2018 at "JAMA Oncology"

DOI: 10.1001/jamaoncol.2017.5332

Abstract: Importance Longitudinal circulating tumor DNA (ctDNA) has been shown to predict response and survival in patients with metastatic melanoma treated with anti–programmed cell death 1 (PD-1) antibodies. Pseudoprogression, defined as radiologic finding of disease progression… read more here.

Keywords: ctdna; response; ctdna profile; disease ... See more keywords
Photo by nci from unsplash

Circulating tumour DNA is a promising biomarker for risk stratification of central chondrosarcoma with IDH1/2 and GNAS mutations.

Sign Up to like & get
recommendations!
Published in 2021 at "Molecular oncology"

DOI: 10.1002/1878-0261.13102

Abstract: Chondrosarcoma (CS) is a rare tumour type and the most common primary malignant bone cancer in adults. The prognosis, currently based on tumour grade, imaging and anatomical location, is not reliable and more objective biomarkers… read more here.

Keywords: chondrosarcoma; ctdna; tumour dna; circulating tumour ... See more keywords
Photo from wikipedia

Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1.

Sign Up to like & get
recommendations!
Published in 2022 at "Molecular oncology"

DOI: 10.1002/1878-0261.13178

Abstract: Failure of colorectal cancer (CRC) treatment is due to residual disease, and its timely identification is critical for patient survival. Detecting CRC-associated mutations in patient circulating cell-free DNA is confounded by tumor mutation heterogeneity, requiring… read more here.

Keywords: tumor; tumor burden; treatment; bcat1 ikzf1 ... See more keywords
Photo by fakurian from unsplash

Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC

Sign Up to like & get
recommendations!
Published in 2022 at "Molecular Oncology"

DOI: 10.1002/1878-0261.13357

Abstract: Brain metastasis (BM) genetically diverges from the primary tumor in non‐small‐cell lung cancer (NSCLC). Hence, accurately capturing clinically relevant alterations is pivotal for the delivery of targeted therapies. Circulating tumor DNA (ctDNA) sequencing has emerged… read more here.

Keywords: ctdna; plasma ctdna; brain; tumor ... See more keywords
Photo by ldxcreative from unsplash

Postoperative circulating tumor DNA can refine risk stratification in resectable lung cancer: results from a multicenter study

Sign Up to like & get
recommendations!
Published in 2023 at "Molecular Oncology"

DOI: 10.1002/1878-0261.13387

Abstract: Circulating tumor DNA (ctDNA) has potential as a promising biomarker for molecular residual disease (MRD) detection in lung cancer. As the next‐generation sequencing standardized panel for ctDNA detection emerges, its clinical utility needs to be… read more here.

Keywords: resectable lung; lung cancer; ctdna; lung ... See more keywords
Photo by nagaranbasaran from unsplash

ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes.

Sign Up to like & get
recommendations!
Published in 2023 at "Molecular oncology"

DOI: 10.1002/1878-0261.13416

Abstract: Taselisib is a potent β-sparing phosphatidylinositol 3-kinase (PI3K) inhibitor that, with endocrine therapy, improves outcomes in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutated (PIK3CAmut) advanced breast cancer. To understand alterations associated with response to PI3K inhibition,… read more here.

Keywords: treated taselisib; ctdna; advanced breast; taselisib fulvestrant ... See more keywords
Photo from wikipedia

Circulating cell‐free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre‐analytical biases

Sign Up to like & get
recommendations!
Published in 2022 at "Hematological Oncology"

DOI: 10.1002/hon.3087

Abstract: Circulating tumor DNA (ctDNA) has become the most investigated analyte in blood. It is shed from the tumor into the circulation and represents a subset of the total cell‐free DNA (cfDNA) pool released into the… read more here.

Keywords: cell; dna; ctdna; hematologic malignancies ... See more keywords
Photo from wikipedia

ANALYSIS OF CIRCULATING TUMOR DNA (ctDNA) IN CEREBROSPINAL FLUID DETECTS THE PRESENCE OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN B‐CELL LYMPHOMAS

Sign Up to like & get
recommendations!
Published in 2019 at "Hematological Oncology"

DOI: 10.1002/hon.3_2630

Abstract: (50%) of available biopsy and ctDNA samples respectively. Concordance between genetic profiles of biopsy and ctDNA was accurate for 22/30 patients (73.3%). Mutations of NFKBIE, TNFAIP3, STAT6, PTPN1, B2M, XPO1, ITPKB, GNA13 and SOCS1were found… read more here.

Keywords: ctdna; presence; analysis circulating; circulating tumor ... See more keywords
Photo by schluditsch from unsplash

Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients

Sign Up to like & get
recommendations!
Published in 2017 at "International Journal of Cancer"

DOI: 10.1002/ijc.30650

Abstract: Cell‐free circulating tumor DNA (ctDNA) in plasma has been used as a potential noninvasive biomarker for various tumors. Our study was performed to evaluate the clinical implications of ctDNA detection in patients with metastatic pancreatic… read more here.

Keywords: metastatic pancreatic; ctdna; treatment; pancreatic cancer ... See more keywords
Photo from wikipedia

Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies

Sign Up to like & get
recommendations!
Published in 2020 at "International Journal of Cancer"

DOI: 10.1002/ijc.33312

Abstract: Studies in multiple solid tumor types have demonstrated the prognostic significance of ctDNA analysis after curative intent surgery. A combined analysis of data across completed studies could further our understanding of circulating tumor DNA (ctDNA)… read more here.

Keywords: ctdna; recurrence; analysis; postsurgery ... See more keywords
Photo by 5tep5 from unsplash

Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection.

Sign Up to like & get
recommendations!
Published in 2022 at "Journal of hepato-biliary-pancreatic sciences"

DOI: 10.1002/jhbp.1282

Abstract: PURPOSE We aimed to clarify the prognostic impact of postoperative circulating tumor DNA (ctDNA) shortly after pancreatectomy in patients with pancreatic ductal adenocarcinoma (PDAC). METHODS Preoperative and paired postoperative blood samples were obtained from 66… read more here.

Keywords: prognostic impact; postoperative ctdna; dna; ctdna ... See more keywords